Home › Companies › PLIANT THERAPEUTICS INC. › 2023-2024

PLIANT THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and PLIANT THERAPEUTICS INC.’s Form 8-K, filed June 14, 2024 (Item 5.07 on EDGAR). Page generated October 18, 2026.

5Ballot items
175Asset managers
996Fund votes
June 13, 2024Meeting date

Results at a glance

Meeting of June 13, 2024: 5 items on PLIANT THERAPEUTICS INC.’s Form 8-K, filed June 14, 2024: 1 approved · 4 without a stated outcome.

Material dissent

Elect Director: Hoyoung Huh, M.D., Ph.D. 75% of votes cast Outcome not stated Director under 80%
2. The Company's stockholders failed to approve, on a non-binding advisory basis, the compensation of the Company's named executive officers 45.3% of votes cast Outcome not stated Say-on-pay under 70%

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025

Explore PLIANT THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by PLIANT THERAPEUTICS INC.

These tallies are PLIANT THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 14, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

PLIANT THERAPEUTICS INC. — official shareholder meeting results, meeting held June 13, 2024
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Hoyoung Huh, M.D., Ph.D.	39,087,800	--	--	12,731,485	--	75%	Not verified	—
Elect Director: Darren Cline, MBA	51,397,449	--	--	421,836	--	99.1%	Not verified	—
Elect Director: David Pyott, MA, MBA	48,388,729	--	--	3,430,556	--	93%	Not verified	—
2. The Company's stockholders failed to approve, on a non-binding advisory basis, the compensation of the Company's named executive officers	23,479,353	28,329,655	10,277	--	--	45.3%	Not verified	a majority of the votes cast
3. The selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm	56,628,368	10,853	62,998	--	--	99.9%	Approved	—

Source: PLIANT THERAPEUTICS INC., Form 8-K, filed with the SEC on June 14, 2024 — read the filing on EDGAR.

How asset managers voted at the PLIANT THERAPEUTICS INC. 2023-2024 meeting

Each item below shows how the 175 asset managers that disclosed a PLIANT THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: Darren Cline, MBA

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

99.1% Majority: yes · of votes cast

FOR 99.1%

FOR: 51,397,449WITHHELD: 421,836

Details: description as filed, official tally, votes by 58 asset managers

Description as filed by funds: To elect three class III directors named in the proxy statement to our Board of Directors: Darren Cline, MBA

PLIANT THERAPEUTICS INC.’s own tally for this item (“Elect Director: Darren Cline, MBA”): 51,397,449 for, 421,836 withheld, per its Form 8-K filed June 14, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.1% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 58 asset managers below reported 12,940,290 for, 248,223 withheld.

FOR

FOR: 12,940,290WITHHOLD: 248,223

Largest asset managers voting on “To elect three class III directors named in the proxy statement to our Board of Directors: Darren Cline, MBA” at PLIANT THERAPEUTICS INC., 2023-2024
Asset manager	For	Withheld	Vote
Vanguard	3,337,958	0	For
T. Rowe Price	2,805,430	0	For
BlackRock	1,479,278	0	For
Capital Group	1,377,327	0	For
Fidelity	903,542	0	For
FRANKLIN STRATEGIC SERIES	829,600	0	For
Charles Schwab	430,892	0	For
Columbia Threadneedle	310,308	0	For
Dimensional	0	183,701	Withhold
Jackson National	162,523	1,526	For
Victory Capital	160,127	0	For
Equitable	99,489	58,180	Mixed
TIAA	146,232	0	For
State Street	77,927	0	For
Lincoln Financial	74,516	2,509	For
Russell Investments	73,106	0	For
American Century	63,652	0	For
WANGER ADVISORS TRUST	58,436	0	For
Nushares ETF Trust	55,828	0	For
ALGER FUNDS	52,723	0	For
John Hancock	48,200	0	For
QUANTITATIVE MASTER SERIES LLC	44,225	0	For
AIG/SunAmerica	31,473	0	For
Harbor Funds II	30,605	0	For
Global X	25,868	0	For

Showing the 25 largest of 58 asset managers. See all 58 in the interactive database.

2. Elect Director: David Pyott, MA, MBA

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%

FOR: 48,388,729WITHHELD: 3,430,556

Details: description as filed, official tally, votes by 58 asset managers

Description as filed by funds: To elect three class III directors named in the proxy statement to our Board of Directors: David Pyott, MA, MBA

PLIANT THERAPEUTICS INC.’s own tally for this item (“Elect Director: David Pyott, MA, MBA”): 48,388,729 for, 3,430,556 withheld, per its Form 8-K filed June 14, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 58 asset managers below reported 11,266,079 for, 1,922,434 withheld.

FORWITHHOLD

FOR: 11,266,079WITHHOLD: 1,922,434

Largest asset managers voting on “To elect three class III directors named in the proxy statement to our Board of Directors: David Pyott, MA, MB” at PLIANT THERAPEUTICS INC., 2023-2024
Asset manager	For	Withheld	Vote
Vanguard	3,337,958	0	For
T. Rowe Price	2,805,430	0	For
BlackRock	0	1,479,278	Withhold
Capital Group	1,377,327	0	For
Fidelity	881,098	22,444	For
FRANKLIN STRATEGIC SERIES	829,600	0	For
Charles Schwab	430,892	0	For
Columbia Threadneedle	310,308	0	For
Dimensional	0	183,701	Withhold
Jackson National	162,523	1,526	For
Victory Capital	160,127	0	For
Equitable	10,520	147,149	Mixed
TIAA	146,232	0	For
State Street	77,927	0	For
Lincoln Financial	74,516	2,509	For
Russell Investments	73,106	0	For
American Century	63,652	0	For
WANGER ADVISORS TRUST	58,436	0	For
Nushares ETF Trust	55,828	0	For
ALGER FUNDS	52,723	0	For
John Hancock	48,200	0	For
QUANTITATIVE MASTER SERIES LLC	0	44,225	Withhold
AIG/SunAmerica	31,473	0	For
Harbor Funds II	30,605	0	For
Global X	25,868	0	For

Showing the 25 largest of 58 asset managers. See all 58 in the interactive database.

3. Elect Director: Hoyoung Huh, M.D., Ph.D.

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

75% Majority: yes · of votes cast

FOR 75%WITHHELD

FOR: 39,087,800WITHHELD: 12,731,485

Details: description as filed, official tally, votes by 58 asset managers

Description as filed by funds: To elect three class III directors named in the proxy statement to our Board of Directors: Hoyoung Huh, M.D., Ph.D.

PLIANT THERAPEUTICS INC.’s own tally for this item (“Elect Director: Hoyoung Huh, M.D., Ph.D.”): 39,087,800 for, 12,731,485 withheld, per its Form 8-K filed June 14, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 75% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 58 asset managers below reported 12,257,179 for, 931,334 withheld.

FOR

FOR: 12,257,179WITHHOLD: 931,334

Largest asset managers voting on “To elect three class III directors named in the proxy statement to our Board of Directors: Hoyoung Huh, M.D., ” at PLIANT THERAPEUTICS INC., 2023-2024
Asset manager	For	Withheld	Vote
Vanguard	3,337,958	0	For
T. Rowe Price	2,805,430	0	For
BlackRock	1,479,278	0	For
Capital Group	1,377,327	0	For
Fidelity	903,542	0	For
FRANKLIN STRATEGIC SERIES	829,600	0	For
Charles Schwab	430,892	0	For
Columbia Threadneedle	310,308	0	For
Dimensional	0	183,701	Withhold
Jackson National	0	164,049	Withhold
Victory Capital	0	160,127	Withhold
Equitable	99,489	58,180	Mixed
TIAA	146,232	0	For
State Street	77,816	111	For
Lincoln Financial	47,300	29,725	Mixed
Russell Investments	73,106	0	For
American Century	0	63,652	Withhold
WANGER ADVISORS TRUST	58,436	0	For
Nushares ETF Trust	55,828	0	For
ALGER FUNDS	0	52,723	Withhold
John Hancock	27,082	21,118	Mixed
QUANTITATIVE MASTER SERIES LLC	44,225	0	For
AIG/SunAmerica	0	31,473	Withhold
Harbor Funds II	30,605	0	For
Global X	25,868	0	For

Showing the 25 largest of 58 asset managers. See all 58 in the interactive database.

4. 2. The Company's stockholders failed to approve, on a non-binding advisory basis, the compensation of the Company's…

Outcome not verified Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Not verified

Combines 6 wordings of this item as funds reported it.

45.3% Majority: no · of votes cast

FOR 45.3%AGAINST

FOR: 23,479,353AGAINST: 28,329,655

Details: description as filed, official tally, votes by 175 asset managers

Description as filed by funds: TO APPROVE, BY NON-BINDING ADVISORY VOTE, THE RESOLUTION APPROVING NAMED EXECUTIVE OFFICER COMPENSATION.

PLIANT THERAPEUTICS INC.’s own tally for this item (“2. The Company's stockholders failed to approve, on a non-binding advisory basis, the compensation of the Company's named executive officers”): 23,479,353 for, 28,329,655 against, per its Form 8-K filed June 14, 2024 (Item 5.07). FOR was not more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 45.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Voting standard, as the filing states it: a majority of the votes cast (“majority of the votes cast”).

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 58 asset managers voting on “TO APPROVE, BY NON-BINDING ADVISORY VOTE, THE RESOLUTION APPROVING NAMED EXECUTIVE OFFICER COMPENSATION.” at PLIANT THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	3,337,958	0	For
T. Rowe Price	0	2,805,430	Against
BlackRock	0	1,479,278	Against
Capital Group	0	1,377,327	Against
Fidelity	307,321	596,221	Mixed
FRANKLIN STRATEGIC SERIES	0	829,600	Against
Charles Schwab	0	430,892	Against
Columbia Threadneedle	0	310,308	Against
Dimensional	0	183,701	Against
Jackson National	0	164,049	Against
Victory Capital	0	160,127	Against
Equitable	0	157,669	Against
TIAA	0	146,232	Against
State Street	77,816	111	For
Lincoln Financial	47,300	29,725	Mixed
Russell Investments	0	73,106	Against
American Century	0	63,652	Against
WANGER ADVISORS TRUST	0	58,436	Against
Nushares ETF Trust	0	55,828	Against
ALGER FUNDS	0	52,723	Against
John Hancock	0	48,200	Against
QUANTITATIVE MASTER SERIES LLC	0	44,225	Against
AIG/SunAmerica	0	31,473	Against
Harbor Funds II	30,605	0	For
Global X	0	25,868	Against

Fund voting reports, all 58 managers: 3,805,035 for, 9,383,478 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 135 asset managers voting on “TO APPROVE, BY NON-BINDING ADVISORY VOTE, THE RESOLUTION APPROVING NAMED EXECUTIVE OFFICER COMPENSATION.” at PLIANT THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Vote
Deep Track Capital, LP	4,415,343	0	For
T. Rowe Price	0	3,571,448	Against
Redmile Group, LLC	0	3,499,816	Against
Laurion Capital Management LP	0	3,474,744	Against
First Light Asset Management, LLC	3,276,945	0	For
TRV GP IV, LLC	2,132,867	0	For
Fidelity	2,077,288	0	For
Polar Capital Holdings Plc	0	1,989,220	Against
GREAT POINT PARTNERS LLC	1,725,936	0	For
FRANKLIN ADVISERS INC	0	1,513,287	Against
Capital Group	4	1,377,327	Against
BlackRock	20,114	1,229,197	Against
PICTET ASSET MANAGEMENT SA	0	1,189,593	Against
State Street	1,047,587	16,864	For
BESSEMER TRUST Co NATIONAL ASSOCIATION	0	1,059,388	Against
RA CAPITAL MANAGEMENT, L.P.	995,286	0	For
Granahan Investment Management, LLC	0	686,064	Against
Citadel	647,300	0	For
GEODE CAPITAL MANAGEMENT, LLC	0	646,434	Against
Candriam S.C.A.	0	548,000	Against
Bessemer Trust CO of Delaware, N.A.	0	541,619	Against
BESSEMER TRUST CO	0	532,079	Against
BESSEMER TRUST Co OF FLORIDA	0	532,079	Against
Bessemer Trust Co of California, N.A.	0	532,079	Against
Bessemer Trust Co of Nevada, National Association	0	532,079	Against

Institutional-manager reports, all 135 managers: 17,465,443 for, 26,004,033 against, 4,535 not voted. Showing the 25 largest; see all in the interactive database.

5. 3. The selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

99.9% Approved · of votes cast

FOR 99.9%

FOR: 56,628,368AGAINST: 10,853

Details: description as filed, official tally, votes by 58 asset managers

Description as filed by funds: To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.

PLIANT THERAPEUTICS INC.’s own tally for this item (“3. The selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm”): 56,628,368 for, 10,853 against — passed, per its Form 8-K filed June 14, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3: The Company's stockholders ratified the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 58 asset managers below reported 13,188,513 for.

FOR

FOR: 13,188,513

Largest asset managers voting on “To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for th” at PLIANT THERAPEUTICS INC., 2023-2024
Asset manager	For	Vote
Vanguard	3,337,958	For
T. Rowe Price	2,805,430	For
BlackRock	1,479,278	For
Capital Group	1,377,327	For
Fidelity	903,542	For
FRANKLIN STRATEGIC SERIES	829,600	For
Charles Schwab	430,892	For
Columbia Threadneedle	310,308	For
Dimensional	183,701	For
Jackson National	164,049	For
Victory Capital	160,127	For
Equitable	157,669	For
TIAA	146,232	For
State Street	77,927	For
Lincoln Financial	77,025	For
Russell Investments	73,106	For
American Century	63,652	For
WANGER ADVISORS TRUST	58,436	For
Nushares ETF Trust	55,828	For
ALGER FUNDS	52,723	For
John Hancock	48,200	For
QUANTITATIVE MASTER SERIES LLC	44,225	For
AIG/SunAmerica	31,473	For
Harbor Funds II	30,605	For
Global X	25,868	For

Showing the 25 largest of 58 asset managers. See all 58 in the interactive database.

Largest PLIANT THERAPEUTICS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 60,325,832 shares outstanding at the time of that meeting.

Fund voting reports: top PLIANT THERAPEUTICS INC. shareholders by shares voted on “TO APPROVE, BY NON-BINDING ADVISORY VOTE, THE RESOLUTION APPROVING NAMED EXECUTIVE OFFICER…”, 2023-2024
#	Asset manager	% of shares outstanding
1	Vanguard	5.53%
2	T. Rowe Price	4.65%
3	BlackRock	2.45%
4	Capital Group	2.28%
5	Fidelity	1.50%
6	FRANKLIN STRATEGIC SERIES	1.38%
7	Charles Schwab	0.71%
8	Columbia Threadneedle	0.51%
9	Dimensional	0.30%
10	Jackson National	0.27%

Institutional-manager reports: top PLIANT THERAPEUTICS INC. shareholders by shares voted on “TO APPROVE, BY NON-BINDING ADVISORY VOTE, THE RESOLUTION APPROVING NAMED EXECUTIVE OFFICER…”, 2023-2024
#	Asset manager	% of shares outstanding
1	Deep Track Capital, LP	7.32%
2	T. Rowe Price	5.92%
3	Redmile Group, LLC	5.80%
4	Laurion Capital Management LP	5.76%
5	First Light Asset Management, LLC	5.43%
6	TRV GP IV, LLC	3.54%
7	Fidelity	3.44%
8	Polar Capital Holdings Plc	3.30%
9	GREAT POINT PARTNERS LLC	2.86%
10	FRANKLIN ADVISERS INC	2.51%

Reported PLIANT THERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

PLIANT THERAPEUTICS INC. holdings and ownership disclosed for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
Deep Track Capital, LP	9.53%	DEF14A
FMR LLC	6.57%	DEF14A
T. Rowe Price	6.56%	13F
First Light Asset Management LLC	6.02%	DEF14A
S F	6.02%	13G
Laurion Capital Management LP	5.94%	DEF14A
Morgan Stanley	5.81%	13F
Blue Owl Capital Holdings L.P.	4.98%	DEF14A
Vanguard Group	4.60%	13F
JPMorgan Chase	3.53%	13F

Percentages above are of 60,325,832 shares outstanding, as reported by PLIANT THERAPEUTICS INC. on its Form 10-Q dated May 1, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from PLIANT THERAPEUTICS INC.’s 10-Q dated May 1, 2024. This page is a static snapshot rebuilt weekly on October 18, 2026; a live search always shows the current data.

At PLIANT THERAPEUTICS INC.'s shareholder meeting held June 13, 2024, in the 2023-2024 proxy season, 175 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 996 separate fund positions. On the most widely held item on that ballot — TO APPROVE, BY NON-BINDING ADVISORY VOTE, THE RESOLUTION APPROVING NAMED EXECUTIVE OFFICER… — FOR was 45.3% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is not more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: PLIANT THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 14, 2024.

PLIANT THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025.

Download data (CSV): ballot items · votes by manager · column guide.